Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model Siska Mortier, Dirk Faict, Norbert.

Slides:

Advertisements

Similar presentations

Home care assistance and the utilization of peritoneal dialysis

Advertisements

Volume 59, Issue 4, Pages (April 2001)

Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model Siska Mortier, Dirk Faict, Norbert.

l-Carnitine is an osmotic agent suitable for peritoneal dialysis

l-Carnitine is an osmotic agent suitable for peritoneal dialysis

Volume 67, Issue 5, Pages (May 2005)

Buffer transport in peritoneal dialysis

Volume 84, Issue 5, Pages (November 2013)

Long-term follow-up of patients randomized to biocompatible or conventional peritoneal dialysis solutions show no difference in peritonitis or technique.

Use of icodextrin in high transport ultrafiltration failure

Volume 62, Issue 2, Pages (August 2002)

Impact of new dialysis solutions on peritonitis rates

Incremental peritoneal dialysis: Effects on the choice of dialysis modality, residual renal function and adequacy G. Viglino, L. Neri, S. Barbieri Kidney.

Volume 53, Issue 4, Pages (April 1998)

Volume 53, Issue 4, Pages (April 1998)

Prenatal exposure to nicotine modifies kidney weight and blood pressure in genetically susceptible rats: A case of gene-environment interaction Zdenka.

l-Carnitine is an osmotic agent suitable for peritoneal dialysis

Volume 64, Issue 2, Pages (August 2003)

Fibrin plug Kidney International Volume 78, Issue 9, (November 2010)

Ho-Han Wu, Szu-Yuan Li, Wu-Chang Yang Kidney International

Fluid overload and residual renal function in peritoneal dialysis: the proof of the pudding is in the eating Wim Van Biesen, Achim Jörres Kidney International

Volume 60, Issue 5, Pages (November 2001)

Volume 78, Issue 6, Pages (September 2010)

E. Boulanger, N. Grossin, M.-P. Wautier, R. Taamma, J.-L. Wautier

Methotrexate in the urine

S.G. John, N.M. Selby, C.W. McIntyre Kidney International

Mohammed S. Razzaque, Ph.D., Takashi Taguchi Kidney International

Comorbidity and confounding in end-stage renal disease

The renin–angiotensin–aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Sharon J. Nessim, Jeffrey.

Volume 86, Issue 6, Pages (December 2014)

Rahi Victory, M. D. , F. R. C. S. C. , Ghassan M. Saed, Ph. D

Volume 73, Pages S5-S17 (April 2008)

Volume 73, Pages S94-S101 (April 2008)

Claudine S. Bonder, Lisa M. Ebert Kidney International

Analysis of fluid transport pathways and their determinants in peritoneal dialysis patients with ultrafiltration failure A. Parikova, W. Smit, D.G. Struijk,

The application of animal models to study the biocompatibility of bicarbonate-buffered peritoneal dialysis solutions P.M. ter Wee, R.H.J. Beelen, J.

Volume 54, Issue 6, Pages (January 1998)

Volume 70, Issue 9, Pages (November 2006)

In vitro biocompatibility performance of Physioneal

Volume 76, Issue 6, Pages (September 2009)

New insights in uremic toxins

Volume 68, Issue 3, Pages (September 2005)

Volume 71, Issue 9, Pages (May 2007)

Clifford J. Holmes, Dirk Faict Kidney International

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Microbiology and outcomes of peritonitis in North America

Nephrology Crossword: Peritoneal Dialysis

Volume 67, Issue 6, Pages (June 2005)

Future of icodextrin as an osmotic agent in peritoneal dialysis

Volume 66, Issue 3, Pages (September 2004)

Volume 60, Issue 6, Pages (December 2001)

Volume 60, Issue 1, Pages (July 2001)

Volume 61, Issue 2, Pages (February 2002)

Volume 55, Issue 3, Pages (March 1999)

Peter G. Blake, Arsh K. Jain, Sechelle Yohanna Kidney International

Volume 70, Pages S84-S90 (November 2006)

Volume 63, Issue 1, Pages (January 2003)

Biocompatibility of icodextrin

Volume 59, Issue 4, Pages (April 2001)

Calcium channel blockers, either amlodipine or mibefradil, ameliorate renal injury in experimental diabetes Guorong Ma, Terri J. Allen, Mark E. Cooper,

Volume 68, Issue 4, Pages (October 2005)

Quantification of free water transport in peritoneal dialysis

Volume 71, Issue 9, Pages (May 2007)

Volume 65, Issue 1, Pages (January 2004)

Volume 70, Issue 10, Pages (November 2006)

The International Pediatric Peritonitis Registry: Starting to walk

Volume 65, Issue 5, Pages (May 2004)

Volume 75, Issue 8, Pages (April 2009)

The biocompatibility of neutral pH, low-GDP peritoneal dialysis solutions: benefit at bench, bedside, or both? Jeffrey Perl, Sharon J. Nessim, Joanne.

Presentation transcript:

Benefits of switching from a conventional to a low-GDP bicarbonate/lactate-buffered dialysis solution in a rat model Siska Mortier, Dirk Faict, Norbert H. Lameire, Ans De Vriese Kidney International Volume 67, Issue 4, Pages 1559-1565 (April 2005) DOI: 10.1111/j.1523-1755.2005.00237.x Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 1 Net ultrafiltration after a 120-minute dwell of 15 mL of 3.86% glucose dialysate in experimental animals exposed to standard lactate-buffered peritoneal dialysis fluid (PDF) for 12 or 20 weeks (N = 9orN = 11, closed bars), low-glucose degradation product (GDP) bicarbonate/lactate-buffered PDF (N = 9orN = 10, open bars) for 12 or 20 weeks, and standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (N = 10, hatched bar).*P < 0.01 vs. Dianeal (20 weeks). Kidney International 2005 67, 1559-1565DOI: (10.1111/j.1523-1755.2005.00237.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 2 Immunostaining for eNOS of the visceral peritoneum (×200) exposed to standard lactate-buffered PDF for 20 weeks (A,N = 11), standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B,N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks (C,N = 10). Kidney International 2005 67, 1559-1565DOI: (10.1111/j.1523-1755.2005.00237.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 3 Vascular endothelial growth factor (VEGF) expression, expressed as percentage staining, was evaluated by a VEGF immunostaining of the visceral peritoneum exposed to standard lactate-buffered PDF for 20 weeks (A,N = 11), standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B,N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks (C,N = 10). Kidney International 2005 67, 1559-1565DOI: (10.1111/j.1523-1755.2005.00237.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 4 Advanced glycation end product (AGE) accumulation, expressed as percentage staining, was evaluated by an AGE immunostaining of the visceral peritoneum exposed to standard lactate-buffered PDF for 20 weeks (A,N = 11), standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B,N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks (C,N = 10). Kidney International 2005 67, 1559-1565DOI: (10.1111/j.1523-1755.2005.00237.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 5 TGF-β expression, expressed as percentage staining, was evaluated by a TGF-β immunostaining of the visceral peritoneum exposed to standard lactate-buffered PDF for 20 weeks (A,N = 11), standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 week (B,N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks (C,N = 10). Kidney International 2005 67, 1559-1565DOI: (10.1111/j.1523-1755.2005.00237.x) Copyright © 2005 International Society of Nephrology Terms and Conditions

Figure 6 Fibrosis was evaluated with a Picro Sirius Red staining of the visceral peritoneum exposed to standard lactate-buffered PDF for 20 weeks (A,N = 11), standard lactate-buffered PDF for 12 weeks followed by exposure to low-GDP bicarbonate/lactate-buffered PDF for 8 weeks (B,N = 10), and low-GDP bicarbonate/lactate-buffered PDF for 20 weeks (C,N = 10). Kidney International 2005 67, 1559-1565DOI: (10.1111/j.1523-1755.2005.00237.x) Copyright © 2005 International Society of Nephrology Terms and Conditions